Cast Your Vote: Select the New EMGS Officers for 2021-2022

The EMGS Nominating Committee has selected the candidates for this year’s election. This year we will be choosing a Vice President-Elect and five Councilors. Each candidate has agreed to volunteer their time and energy to serve both the Society and its members. 

VOTING DATES: September 27 - October 17, 2021.

Vote Now!

Vice President-Elect Candidates

Screenshot (29).png

Patricia L. Opresko, PhD

 University of Pittsburgh

Dr. Patricia L. Opresko is a tenured Professor in the Department of Environmental and Occupational Health at the University of Pittsburgh Graduate School of Public Health.  She holds a secondary appointment in the Department of Pharmacology and Chemical Biology at the School of Medicine.  Patty is Co-Leader of the Genome Stability Program at the UPMC Hillman Cancer Center, and a member of the Center for Nucleic Acid Science and Technology at Carnegie Mellon University. She received her BS from DeSales University in Chemistry and Biology and her doctorate from the Pennsylvania State University College of Medicine in Biochemistry and Molecular Biology.  Patty conducted her postdoctoral training with Dr. Vilhelm Bohr at the National Institute on Aging studying the molecular pathology of Werner Syndrome, a cancer-prone premature aging disorder. She started her laboratory in 2005, investigating mechanisms of genomic and telomere instability associated with aging and cancer. Her lab studies how environmental genotoxic and oxidative stress accelerate telomere shortening, and roles for DNA damage and repair in telomere maintenance.  In 2006, Patty received the Ellison Medical Foundation New Scholars Award in Aging and the Outstanding New Environmental Scientist Award. She is currently a principal investigator on an R35 RIVER grant from the National Institute of Environmental Health Sciences and co-PI on a National Cancer Institute R01 grant.

Patty Opresko is internationally recognized for her work in genome stability, telomere biology and DNA repair, and has published over 80 peer-reviewed manuscripts.  She is an Associate Editor for Mechanisms of Development and Aging and an editorial board member of DNA Repair.  She served on numerous review panels of research proposals for NIH and other organizations, and is currently on the NIEHS Environmental Health Sciences Review Committee.  Patty was recently elected as Vice Chair of the Gordon Research Conference on Mammalian DNA Repair in 2021, and Chair in 2023.  She has given several Keynote lectures and received numerous awards including the Glenn Award for Research in Biological Mechanisms of Aging (2019) and the Merrill J. Egorin Excellence in Scientific Leadership Award (2020).  She is greatly involved in graduate and postdoctoral mentoring across several departments at the University of Pittsburgh and teaches in Genetic Toxicology, Biology of Aging and Genome Instability graduate courses.

Patty has been highly active in EMGS since joining in 2005 and has regularly participated in the annual meetings by presenting seminars and co-chairing sessions.  She served on the Program (2008), Awards and Honors (2011-2013), Finance (2017-2020), and Executive (2018-2019) Committees.  Patty was elected to serve as a Councilor (2017-2020) and as the DNA Repair SIG Representative to the Program Committee (2020-2022).  She also participated in several International Conferences on Environmental Mutagens. Patty has encouraged her students and postdocs to attend EMGS meetings to take advantage of the terrific science, and valuable structured opportunities for networking and career development. She values EMGS for the opportunities to participate in a scientific society that shares her interests in genome stability, genotoxic exposures and human health, and looks forward to continued EMGS growth and advancement.  


Smith-Roe EMGS Bio Picture.pngStephanie Smith-Roe, PhD

Division of the National Toxicology Program

Stephanie Smith-Roe, Ph.D., is a genetic toxicologist in the Systems Toxicology Branch of the Division of the National Toxicology Program (DNTP) at NIEHS.  The NTP generates “science you can depend on for decisions that matter” by conducting toxicological evaluations of chemicals and substances that are of concern to the general public and various stakeholders using guideline studies and new testing approaches.  Dr. Smith-Roe designs genetic toxicity testing strategies for the NTP and serves as the Contracting Officer’s Representative for the program’s Genetic Toxicity Testing Contract.  She is the lead study scientist for the in vitro genetic toxicity testing of glyphosate (the active herbicide in Roundup products) and has investigated the genotoxic effects of other high-profile exposures such as radiofrequency radiation and botanical dietary supplements.  She has collaborated with academic laboratories and companies to assess new approaches for identifying genotoxicants, including Duplex SequencingTM, CometChip technology, and multiplexed flow cytometry assays designed to identify mode-of-action and mechanism-of-action for genotoxicants.  Dr. Smith-Roe has contributed to the Toxicology in the 21st Century quantitative high-throughput screening effort to prioritize chemicals for further testing, focusing on assays that detect DNA damage.  Her expertise has been recognized internationally, e.g., as an IARC monograph work group participant.

Dr. Smith-Roe acquired training in toxicology and molecular biology in the pursuit of understanding the causes and consequences of genomic instability, with an emphasis on the effects of environmental exposures.  Before joining the NTP, she held a Curriculum in Toxicology Postdoctoral Fellowship at UNC-Chapel Hill where she examined the contribution of DNA replication fork protection proteins to the maintenance of genomic stability in Dr. William Kaufmann’s laboratory.  She obtained her Ph.D. in the Department of Environmental and Molecular Toxicology at Oregon State University.  Altogether, she has published in the areas of mutagenesis, carcinogenesis, DNA replication and repair, DNA damage signaling, chromatin remodeling, and genetic toxicology. 

Dr. Smith-Roe has actively contributed to the scientific and professional development goals of the EMGS.  Since joining in 2003, she has chaired symposia, forums, and platform sessions for annual meetings, chaired the New Technologies Special Interest Group, and is an Editorial Board member of Environmental and Molecular Mutagenesis.  She chairs the Membership and Professional Development Committee, has chaired the Education, Student, and New Investigator Affairs Committee, and served on Council and was a Council Liaison to the Executive Board.  She has also contributed to the Brand Identity, Meeting Structure, and New Directions Task Forces and other efforts to ensure that EMGS meets the needs of membership.  Dr. Smith-Roe has served in leadership roles in other scientific organizations as well; for example, she Co-Chairs the In Vitro Work Group for the HESI Genetic Toxicology Technical Committee (GTTC), an international community of genetic toxicologists from industry, government, and academia.  Dr. Smith-Roe enjoyed serving as President of the Genetics and Environmental Mutagenesis Society (GEMS), local to the Research Triangle Park in North Carolina.  Dr. Smith-Roe is excited with the possibility of applying her extensive institutional knowledge of EMGS to the continued the success and growth of the society.

                                                                    


Councilor Candidates

Miller_Colette_2.jpgColette Miller, PhD

U.S. Environmental Protection Agency

Dr. Colette Miller is a Biologist at the U.S. Environmental Protection Agency in the Center for Public Health and Environmental Assessment located in Research Triangle Park, NC. After obtaining her Ph.D. in Nutrition from the University of Georgia in 2014, Dr. Miller began postdoctoral work at the U.S. EPA studying the effects of air pollution on maternal and fetal health. She recently has transitioned to an independent investigator role that focuses on the Developmental Origins of Health and Disease hypothesis. Her lab studies the generational cardiometabolic disease risk attributed to exposure to environmental pollutants in both mothers and fathers using rodents as a model system.

With experience and expertise in physiology and molecular biology, Dr. Miller’s lab studies how air pollutants may impede a healthy pregnancy and how that can infer disease risk in the developing offspring. Her research seeks to integrate phenotypic endpoints with molecular mechanisms, exploring how environmental stressors can impact critical steps in pregnancy, such as trophoblast invasion and placentation. Her lab also investigates the epigenetic mechanisms that impart these effects, including studying the role that sperm-derived non-coding RNAs play in driving adverse pregnancy outcomes and programming of metabolic disease risk.

To date, her work has been published in high-profile journals, including Environmental Health PerspectivesMolecular Metabolism, and Obesity. Attributable to her postdoctoral research program, Dr. Miller was recognized in the 2019 Future Research Leaders Conference held by the National Institutes of Health. Furthermore, she has received early career research awards from numerous scientific societies, including the American Physiological Society, Genetics and Environmental Mutagenesis Society, and the Society of Toxicology. Dr. Miller currently serves on the Editorial Board for Reproductive Toxicology and Frontiers in Toxicology and holds active memberships in the American Society for Nutrition, Environmental Mutagenesis and Genomics Society, and the Society of Toxicology. 


Screenshot (31).pngLuoping Zhang, PhD

University of California, Berkeley

Dr. Luoping Zhang is an Adjunct Professor of Toxicology in the Division of Environmental Health Sciences, School of Public Health at the University of California, Berkeley where she has been employed since 1992. For the past 30 years, her research has focused on investigating the molecular mechanisms of carcinogenesis and toxicity caused by human exposures to toxic environmental chemicals, including benzene, formaldehyde, tricholoroethylene, and, most recently, glyphosate and PFASs. In order to explore and identify the mechanisms of disease associated with these chemical exposures, Dr. Zhang and her research team have developed and continue to employ many high-throughput technologies, such as the innovative OctoChrome FISH device for a chromosome-wide aneuploidy study (CWAS) and array-based toxicogenomic and epigenomic tools in their molecular epidemiological studies. Most recently, Dr. Zhang has applied CRISPR technology to investigate the toxic effects induced by various chemical exposures, and the underlying mechanisms by which they operate.

Dr. Zhang has been an active member of EMGS since 2001 and served as a member of Alexander Hollaender Outreach Committee (AHOC). Over the years, she has proposed, organized, and chaired multiple symposiums at the EMGS annual meetings. Dr. Zhang has also served on the Board of Editors for EMGS Environmental and Molecular Mutagenesis Journal since 2012. Additionally, Dr. Zhang was appointed by former California Governor Brown to the Carcinogen Identification Committee, where she has served as a member since 2012. She has also served on various committees for Institute of Medicine at the National Academies, the US EPA, and IARC.


SM_Pic_1.jpg.jpegSheroy Minocherhomji, PhD

Amgen

Dr. Sheroy Minocherhomji is currently a Senior Scientist/Toxicologist and Head of the Genetic Toxicology Unit at Amgen where he is the non-clinical regulatory toxicology lead for several novel first-in-class therapeutics at various stages of development. He also heads Amgen’s Genetic Toxicology Unit that assesses genotoxicity of portfolio molecules and leads efforts to advance cancer risk assessment of therapeutics. He has >10 years of academic and industry experience across discovery and translational research in the cross-disciplinary fields of regulatory toxicology, discovery toxicology, human disease genetics/epigenetics, DNA repair, genome stability and cancer biology.

Dr. Minocherhomji received his M.Sc. degree in Human Molecular Genetics from Imperial College London, UK and a PhD in Health & Medical Sciences as a Marie Curie Fellow from the University of Copenhagen, Denmark that focused on the characterization of novel genetic/epigenetic mechanisms that deregulate disease-associated genes in the human genome. Following the completion of his PhD, he carried out post-doctoral research as a Danish Medical Council fellow that involved the characterization of novel backup DNA repair pathways cells use to replicate their DNA & maintain genome stability in the lab of Prof. Ian D. Hickson at the University of Copenhagen, Denmark.

Dr. Minocherhomji has authored more than 15 peer-reviewed publications including 10 as first/co-first author in high-impact journals including Nature, Nature Cell Biology, Molecular Cell and PNAS including his discovery of the Mitotic DNA Synthesis (MiDAS) pathway that causes the chromosome fragility phenotype and more recently his work around error-corrected next generation sequencing (ecNGS) to advance genotoxicity and cancer risk assessment of therapeutics.

Dr. Minocherhomji has been the recipient of numerous international awards and grants throughout his career, and most recently the Early Stage Investigator and Emerging Scientist Awards by the Genetic Toxicology Association (GTA) and the EMGS. He is a member of the GTA’s board of directors and is also a co-chair of the Error-corrected Sequencing working group of HESI’s Genetic Toxicology Technical Committee (GTTC).


John Pierce Wise Sr.jpgJohn Wise, PhD

Louisville University

Dr. John Pierce Wise, Sr. is a long time member of the Environmental Mutagenesis and Genomics Society (EMGS) and the recipient of its education award. He is currently a Professor of Toxicology and Pharmacology, Distinguished University Scholar, Director of the Center for Occupational and Environmental Health Sciences, and Deputy Director of the National Institutes of Environmental Health Sciences (NIEHS)–funded Center for Integrative Environmental Health Sciences and Multi-Principal Investigator for the NIEHS T32-funded UofL Environmental Health Sciences Training Program. His formal education includes a Bachelor's degree in Biology with high distinction and recognition from George Mason University and a Ph.D. in Pharmacology from the George Washington University. His postdoctoral training focused on molecular epidemiology under Curtis Harris at the National Cancer Institute, followed by experience with occupational health and risk assessment as a Senior Toxicologist at Jonathan Borak and Company. He has served on the faculty of Yale University’s School of Medicine and School of Public Health, the University of Southern Maine, prior to joining the faculty at the University of Louisville, School of Medicine.

Dr. Wise’s research focuses on understanding how environmental toxicants affect health and cause cancer from a One Environmental Health perspective considering cellular and molecular mechanisms in both humans and wildlife, with a particular emphasis on lung cancer and chromosome instability. More specifically, he has made important advances in understanding how metals induce genotoxicity, inhibit DNA repair resulting in chromosome instability and neoplastic transformation. He has been pioneering efforts to learn how metals impact homologous recombination repair and centrosome biology in order to elucidate the mechanisms that underlie structural and numerical chromosome instability caused by metal exposure. He has pursued these areas predominately with mechanistic studies in human cells, but also in cells from other species including fish, whales, sea turtles and sea lions and in novel research platforms such as zero gravity flights and high-altitude ballooning with NASA. Through this work, he and his team have identified key insights into the mechanism of metal-induced carcinogenesis in human lung cells, determined what aspects are conserved across species and used these species and novel platforms to provide novel insights into metal carcinogenesis. In addition to extensive exposure at scientific conferences and in the scientific literature, his work has been featured in numerous articles in local, national and international press and social media sites including short documentaries with Alexandra Cousteau and Miles O’Brien.

Dr. Wise has a strong record of leadership, mentorship and ground breaking environmental health research, particularly in metal carcinogenesis. He has trained over 200 diverse individuals in environmental health at faculty, postdoctoral fellow, graduate student, undergraduate student and high school student levels. His students have won numerous local, national and international awards and grants and have gone onto successful careers in academia, government, industry and non-governmental organizations. In recognition of his research, mentoring and teaching excellence, he was awarded the Metals Career Achievement award from the Society of Toxicology and education awards from both EMGS and SOT.


Mike Fasullo higher resolution-2 (1).jpgMichael Fasullo, PhD

State University of New York Polytechnic Institute 

Dr. Michael Fasullo is an Associate Professor at State University of New York (SUNY) Polytechnic Institute and an adjunct professor in the School of Public Health, SUNY at Albany. He is also a member of the RNA Institute at SUNY Albany. He has more than 33 years of experience in the field of genetic toxicology and has been a member of EMGS for over 25 years.

Michael obtained his B.S. from Massachusetts Institute of Technology and a Ph.D. from Stanford University, where he investigated mechanisms of genome rearrangements using budding yeast strains specifically designed to measure unequal sister recombination, translocations, and gene conversion. These assays have been useful for designing similar assays in mammalian cells. He then conducted postdoctoral studies at Columbia University where he investigated the recombinogenic effects of radiation and chemical carcinogens. These studies were continued at the Stritch School of Medicine (Loyola University) before joining the Albany Medical College and SUNY Polytechnic Institute. A major emphasis of his work has been investigating mechanisms by which cell cycle checkpoints suppress radiation and carcinogen-associated genome instability.  To metabolically activate carcinogens, his recent work focused on expressing human cytochrome P450 (CYP) genes in budding yeast, and performing high throughput screens to identify genes that confer resistance to food carcinogens. These screens have identified novel genes that suppress aflatoxin-associated mutations. An interesting spinoff has led to methods to phenotype CYP polymorphisms using genotoxic endpoints in budding yeast. His research has been funded by governmental agencies, including National Cancer Institute, National Institute of Environmental Health Sciences, Department of Defense, and by private granting agencies, including the March of Dimes and Leukemia Research Foundation. He actively collaborated with a broad range of international scientists and has participated in interdisciplinary panels sponsored by the National Academy of Sciences Keck Futures Initiative, including The Genomic Revolution -- Implications for Treatment and Control of Infectious Disease (2006) and Nuclear Technologies (2013).

He continually advocates for research and pre- and postdoctoral training using model organisms as a reviewer on NIH, NSF and NASA review panels. He has mentored many undergraduates in the laboratory, who have further pursued careers in medicine, engineering, and biomedical science. His excellence in teaching genetic toxicology and biochemistry was recognized by the undergraduate student association for SUNY Polytechnic Institute in 2021.

Michael has attended and spoken at multiple EMGS meetings and credits his first successful NIH application to suggestions from EMGS members. He is a strong advocate for networking among faculty, researchers, trainees, and postdoctoral fellows. He currently participates in multiple SIGS, including DNA Repair and Genomics and Data science. He looks forward to attending and participating in the 2021 EMGS meeting.


2019 Headshot Clint Valentine.jpgClint Valentine, MSc

TwinStrand Biosciences

Clint Valentine is experienced in the fields of genomics, genetic toxicology, and analytical chemistry. Clint earned his early career training as a research assistant in the lab of Dr. John Essigmann within the Biological Engineering department of MIT. These experiences laid the foundation for Clint’s passionate interest in mutagenesis, the initiating events of carcinogenesis, and cancer progression. At MIT, Clint was one of the first to use the Transgenic Rodent (TGR) assay and Duplex Sequencing (an advanced form of error-corrected NGS) to study the mutagenic effects of the health-relevant environmental mycotoxin Aflatoxin B1 in an exposed murine transgenic model. Clint and his colleagues published results that revealed an induction of mutagenesis before phenotypic changes appeared mere weeks after mutagen exposure. The impact of this work has had a significant effect on the utility of using high-throughput genomics for mutational research, drug & chemical safety assessment, and cancer risk evaluation in humans.

After Clint’s experience at MIT, he transitioned from toxicology to computational biology and his goal evolved into commercially developing Duplex Sequencing into a regulated assay for genetic toxicology endpoints. Clint joined TwinStrand Biosciences as one of the earliest employees and simultaneously began studying bioinformatics through a Master of Bioinformatics program offered by Northeastern University, which he later earned in 2017.

During Clint’s tenure at TwinStrand Biosciences, he built a computational biology department. In 2019, Clint was promoted to direct the department, and he now leads over a dozen doctorate-level scientists and engineers who focus on building assays that apply to early cancer detection, cancer monitoring, forensics, and, importantly, genetic toxicology, among others.

In Clint’s current role as a Director of Computational Biology, he practices good scientific stewardship through the continued publication and presentation of peer-reviewed works, collaboration with industrial, academic and government groups, as well as volunteering with EMGS as a Special Interest Group co-chair, which he intends to increase commit towards.


ZhannaSobol.jpgZhanna Sobol, PhD

Merck Research Laboratories 

Zhanna Sobol is an applied genetic toxicologist with over 13 years’ experience in the pharmaceutical industry.  Prior to joining Pfizer Worldwide Research and Development in 2008, she received her graduate degree in Molecular Toxicology from University of California, Los Angeles where she studied mechanisms of DNA damage and repair. In 2021, Zhanna joined Merck Research Laboratories as the lead of the Genetic Toxicology Group. Over the years, she has participated in various organizations and working groups including HESI-Genetic Toxicology Technical Committee, the Genetic Toxicology subcommittee of the Oligonucleotide Safety Working Group and the Genetic Toxicology Association where she served as board member and chair. Zhanna’s work includes risk management of positive genotoxicity findings, risk assessment of novel therapeutic modalities and application of new tools and concepts to address challenges in applied genetic toxicology. 


stephenfergusonphoto.jpgStephen Ferguson, PhD

Division of the National Toxicology Program/ National Institute of Environmental Health Sciences 

Dr. Stephen Ferguson is a multidisciplinary scientist within the National Toxicology Program Division (DNTP) of the National Institute of Environmental Health Sciences (NIEHS). Ferguson serves multiple roles within DNTP that include:  1) leading research efforts to develop, qualify, and apply physiologically relevant in vitro toxicology models (i.e., 3D, ADME, microphysiological), 2)integrating informative assay platforms (e.g., high throughput transcriptomics, imaging, cellular health/toxicity) that help to shape the path forward for human translational toxicology research, and 3) evaluating the toxicity potential of DNTP test chemicals (e.g., PFAS, botanicals, polycyclic aromatic hydrocarbons, and other environmental chemicals) using computational, in vitro, and in vivo model systems. Prior to joining the NTP, Ferguson led the ADME/Tox R&D program of Life Technologies (now Thermo-Fisher) where he and his team developed predictive in vitro liver models and assay approaches for estimation of human drug metabolism, transport, liver toxicity, and drug-drug interactions. Steve received his BS and PhD in chemistry from NC State University with a focus on molecular biology and the roles of transition metals within biological systems, and currently serves as adjunct faculty to the Curriculum in Toxicology at the UNC-CH. 


Shobhan_2.pngShobhan Gaddameedhi, PhD

North Carolina State University

Dr. Shobhan Gaddameedhi is a tenured Associate Professor of Biological Sciences and the Toxicology Program at North Carolina State University (NCSU). Shobhan received his master’s degree from the University of Hyderabad, India and his PhD degree from North Dakota State University (2003-2008). He pursued his post-doctoral training in circadian biology and DNA repair with Prof. Aziz Sancar, at UNC Chapel Hill (2008-2014). Before joining NCSU as part of the Chancellor’s Faculty Excellence Program in Environmental Health Sciences in July 2020, he worked as an Assistant Professor at Washington State University (2014-2020). Shobhan is a recipient of NIH/NIEHS K99/R00 Career Development Award (2013), DOD/CDMRP Career Development Award (2018), and NIH/NIEHS Outstanding New Environmental Scientist/ONES Award (2020). In addition, he is a recipient of UNC Postdoctoral Award for Research Excellence (2013), American Society for Photobiology New Investigator Award (2018), and Environmental Mutagenesis and Genomics Society (EMGS) Newly Independent Investigator Program Award (2018).

Shobhan’s main scientific interests are determining the mechanisms by which the circadian clock regulates environmental health outcomes through ‘gene-environment’ interactions and identifying the mechanisms by which circadian disruption, through rotating night-shift work/jetlag in humans, influences solar UVB-mediated DNA repair and environmental carcinogenesis. Shobhan hopes to translate these findings into therapeutic treatments for human skin disorders.

Shobhan believes that EMGS provides an unique opportunity to engage with renowned scientists within the DNA repair, genotoxicity, and environmental carcinogenesis scientific fields. From Shobhan’s active involvement the past seven years, he has been able to develop a strong network of colleagues and collaborators across the environmental mutagenesis and genomics scientific world. This experience has prepared him to draw expert experience to EMGS leadership assembling high quality leadership capable of providing substantial advice and support for continuing growth and long-term sustainability of the EMGS.

Most importantly, EMGS deeply cares for the next generation of scientists including students, post-doctoral fellows, and newly independent investigators of environmental health sciences research. Being a part of this amazing society’s leadership, he will have the wonderful opportunity to share his professional experience and scientific knowledge to challenge and develop the current and future generation of scientists in the environmental health sciences research field


Endowment Fund Chair Candidates

Miriam Poirier.jpgMiriam C. Poirier, PhD

National Cancer Institute- Retired 

Miriam C. Poirier Ph.D., who is currently a Scientist Emeritus at the National Cancer Institute (NCI), NIH, was Head of the Carcinogen-DNA Interactions Section (1997-2015) in the Laboratory of Cancer Biology and Genetics. She recognized internationally for pioneering the determination of DNA adducts and their sequelae in humans. Her studies have focused on the genotoxicity of carcinogenic polycyclic aromatic hydrocarbons (PAHs), as well as genotoxicity and mitochondrial toxicity of pharmaceuticals including cisplatin, tamoxifen and the antiretroviral nucleoside reverse transcriptase inhibitors (NRTIs) used for therapy of HIV-1. Dr. Poirier’s research, conducted with technicians, students, postdocs and collaborators, provided important insights into mechanisms of cancer causation in humans. She initiated the development of carcinogen-DNA adduct antisera, which were used to determine DNA adducts by immunoassay and immunohistochemistry in human tissues. Her studies showed a correlation between high levels of cisplatin-DNA adducts and favorable disease response in ovarian cancer patients. They also demonstrated incorporation of the NRTI zidovudine (AZT) into leukocyte DNA of infants born to HIV-1-infected mothers receiving NRTI therapy. Further studies showed DNA incorporation, mutagenesis, and tumor formation in mouse offspring exposed to AZT during gestation, suggesting that human infants exposed in utero may be at risk for cancer later in life. In primate offspring born to dams receiving human-equivalent doses of antiretroviral drugs during gestation, genotoxic changes were shown to persist in bone marrow stem cells at 3 yr of age (equivalent to a 15 yr old human). Dr. Poirier’s NRTI studies resulted in several alterations in public health policy, including changes in the Informed Consent for NIH-funded studies involving AZT, changes in the package insert for AZT, and changes in the CDC Guidelines for use of antiretroviral drugs in pregnant women infected with HIV-1. On the strength of these studies, Dr. Poirier was invited to chair a meeting of the International Agency for Research on Cancer that considered a potential human cancer risk of AZT. Late in her career Dr. Poirier pioneered the documentation of PAH-DNA adducts in beluga whale small intestine in a study linking high gastrointestinal cancer rates with PAH exposure in the beluga aquatic environment.  

Dr. Poirier is first or co-author of more than 275 publications and 400 abstracts, and has served in an advisory capacity on numerous US Government and non-Government committees. She received the Society of Toxicology (SOT) Women in Toxicology Service Recognition Award (2007), the NCI Leading Diversity Award (2012), and the NCI WSA Mentoring and Leadership Award (2014).  A previous Environmental Mutagenesis and Genomics Society (EMGS) Council member, Dr. Poirier also served as Chair of both the EMGS Molecular Epidemiology Special Interest Group and the EMGS Publications Policy Committee. She is a past President of the Society of Toxicology Carcinogenesis Specialty Section. In 2015 Dr. Poirier received the Genetic Toxicology Association (GTA) Excellence in Science Award and the EMGS Alexander Hollaender Award. Subsequently she served GTA as an Executive Board member, and EMGS as Program Chair in 2018, President in 2019, and Past President and Chair of the Nominating Committee in 2020.